Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02274051
Other study ID # 09-0762
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 2009
Est. completion date May 4, 2019

Study information

Verified date June 2019
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study of kinetin, a nutritional supplement that corrects the mRNA splicing defect in patients with familial dysautonomia (FD, also known as Riley Day syndrome or hereditary sensory and autonomic neuropathy type III). FD is a rare fatal autosomal recessive disease in which the growth and development of selective neuronal populations is impaired. The disease is the result of a point mutation in the gene sequence that encodes for kinase complex associated protein (IKAP) in chromosome 9q31. The mutation, at the start of the non-encoding intron 20, weakens the splice site, causing the spliceosome to wrongly join together exons 19 and 21 when transcribing the mRNA strand and miss out exon 20. The mutated mRNA produces a short unstable IKAP protein that is quickly degraded. Interestingly, the mutation does not lead to a complete loss of function. Instead, it results in a tissue specific deficiency in splicing efficiency with both normal (wild type) and mutant IKAP mRNA being expressed in different ratios in different tissues. Some cells, like fibroblasts, produce mostly normal mRNA and protein, where as others, like neurons, produce mostly mutant mRNA and almost no functional protein product.


Description:

Familial dysautonomia (FD, also called Riley Day syndrome or hereditary sensory and autonomic neuropathy type III) is an autosomal recessive disease caused by a point mutation in the kinase complex associated protein (IKAP) gene sequence (1, 2). This leads to a tissue specific splicing defect with variable "skipping" of exon 20 (1, 3, 4). The consequence is a devastating congenital sensory neuropathy, affecting pain and temperature perception (5) as well as afferent information from the viscera (6). As a result, patients suffer recurrent aspiration pneumonias, respiratory insufficiency, proprioceptive ataxia, scoliosis and the long-term consequences of volatile blood pressure including renal failure (7) and left ventricular hypertrophy (8).

In-vitro studies have shown that the plant hormone kinetin corrects the splicing defect and increases the production of normal IKAP protein levels in FD derived cell lines (9, 10). Preliminary studies in heterozygous carriers of the IKAP mutation showed that dietary supplementation with kinetin increased the production of correctly spliced IKAP mRNA, in white blood cells (11). Preliminary studies in patients with FD have demonstrated that kinetin also increases the expression of correctly spliced IKAP mRNA extracted from white blood cells. However, the effect of kinetin on mRNA levels in neuronal tissue is unknown.

The overall objective of this study is to assess the safety and tolerability of administering kinetin in patients with FD. The specific aim of this proposal is to determine the safety of a once daily dose of kinetin in patients with FD using a dose ascending titration and to determine the long-term safety and tolerability during 3-years of receiving a maximum tolerated steady state dose of kinetin. The investigators hope to also demonstrate early proof of concept that kinetin enhances the ability of neuronal tissue to correctly splice IKAP mRNA.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date May 4, 2019
Est. primary completion date May 4, 2019
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria:

1. Male of female patients aged 16 and older

2. Confirmed diagnosis of familial dysautonomia by genetic testing

3. Written informed consent to participate in the trial and understanding that they can withdraw consent at anytime without affecting their future care.

4. Ability to comply with the requirements of the study procedures.

Exclusion Criteria:

1. Patients who have taken other nutritional supplements that may affect IKAP mRNA splicing within the last 30 days

2. Patients with a known hypersensitivity to any component of the nutritional supplement kinetin

3. Patients with atrial fibrillation, angina or an electrocardiogram documenting significant abnormality that may jeopardize the patient's health.

4. Patients with significant pulmonary, liver, renal (creatinine >2.5 mg/ml) or cardiac illness

5. Women who are pregnant or lactating

6. Women of childbearing potential who are not using medically accepted methods of contraception.

7. Patients who have a significant abnormality on clinical examination that may, in the investigator's opinion, jeopardize their healthy participating in this pilot trial.

8. Patients taking allopurinol, other xanthine oxidase inhibitors or other compounds that may interfere with the metabolism of kinetin including oral calcium supplements.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Kinetin
Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.

Locations

Country Name City State
United States NYU Langone Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Safety blood labs safety blood labs (CBC, metabolic panel) At baseline and after each 6 months period and at 36 months
Primary Change in vital signs Sitting and standing blood pressure measurements and heart rate At baseline and after each 6 months period and at 36 months
Primary Change in ECG 12 lead ECG measures At baseline and after each 6 months period and at 36 months
Primary Number of participants with adverse events Number of adverse events At baseline and after each 6 months period and at 36 months
See also
  Status Clinical Trial Phase
Withdrawn NCT02608931 - The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia Phase 2
Completed NCT02276716 - The Nutritional Supplement Phosphatidylserine in Patients With Familial Dysautonomia Phase 2
Completed NCT01987219 - The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia Phase 3
Completed NCT01999257 - Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. N/A
Completed NCT03013777 - A Trial of Cognitive Behavioral Therapy in Familial Dysautonomia N/A
Completed NCT01212484 - Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia Phase 3
Not yet recruiting NCT06128356 - Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia Phase 2
Not yet recruiting NCT06148311 - Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia Phase 2
Withdrawn NCT03911063 - Telemedicine Clinical Trial for Cognitive Behavioral Therapy in Familial Dysautonomia N/A